Industry Verticals »

All Categories

Insights »

About TMR »

Alpha Mannosidosis Market

Alpha Mannosidosis Market (Treatment - Bone Marrow Transplant (BMT) and Enzyme Replacement Therapy (ERT); Indication - Type I, Type II and Type III; End Users - Hospitals and Specialty Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global alpha mannosidosis market for the historical period 2017–2018 and forecast period 2019–2027, market exclusivity for orphan drugs, increasing investment in rare disease treatment, and faster market access are projected to drive the global alpha mannosidosis market during the forecast period
  • According to the report, the global alpha mannosidosis market was valued at US$ 7.6 Mn in 2018 and is anticipated to expand at a CAGR of 9.9% from 2019 to 2027

Market Exclusivity for Orphan Drugs and Increasing Investment in Rare Disease Treatment: Key Drivers

  • The most important financial incentive of orphan drug approval for pharmaceutical companies is the market exclusivity of several years for products that have been designated as orphan drugs.
  • This allows pharmaceutical companies to recover costs incurred in development, as during this period regulatory agencies cannot approve a generic equivalent of the drug for the same rare indication.
  • In the U.S., the period for market exclusivity for orphan drugs is 7 years and in the EU it is 10 years. Similar incentives exist in Japan and Australia, among other major regions
  • Smaller clinical trial size, shorter trial time, and commercial benefits such as fast track approval, and fee waivers attract multinational corporations to invest in the rare disease segment
  • The regulatory environment has been more advantageous for developers since the passage of the 1983 Orphan Drug Act. Moreover, venture capitalists see the legislative incentives as a major opportunity to create returns on their investments
  • Moreover, saturation of the markets for diseases with large patient populations, such as asthma, diabetes and hypertension, has led to the focus of pharmaceutical industry towards more specialist, niche diseases where the unmet need is more substantial and the barriers to entry are much lower.

Fee Reductions & Tax Credits Boost Market Growth

  • Orphan drug designation qualifies the orphan drug manufacturer to claim tax credits of up to 50% of R&D costs incurred during the clinical trial phase in the U.S.
  • According to a study conducted by the U.S. Congress, Office of Technology Assessment (OTA, 1993), overall the tax credit lowers the cost of the extra dollar of clinical orphan research by 24% compared to cost without tax credit
  • Similar incentives include FDA fee waivers that reduces transaction cost associated with the approval process
  • Therefore, fee reductions & tax credits is likely to increase demand for alpha mannosidosis globally

High Cost of Treatment to Hamper Market

  • The most important barrier in this market is high cost of producing an orphan drug. The number of patients eligible to receive an orphan drug confines a company's ability to recover its R&D investment.
  • Manufactures require incentives to develop orphan drugs. This being a narrow market, profit is based on supply and demand. By order of magnitude, these orphan drugs are more expensive.
  • High investment involved in research and costs incurred for production of recombinant enzymes, increases cost of ERT. The per year treatment cost of a single lysosomal storage disorder patient is several hundred thousand dollars. Also, such high costs are acceptable in developed countries with established reimbursement structure however, in underdeveloped countries these are unaffordable and limits the access.

Global Alpha mannosidosis Market: Competitive Landscape

  • This report profiles major players in the global alpha mannosidosis market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global alpha mannosidosis market is highly consolidated, with the presence of very few players
  • The only player operating in the global alpha mannosidosis market is Zymenex A/S

Global Alpha mannosidosis Market: Key Developments

  • CHIESI Farmaceutici S.p.A has adopted the business strategy of mergers and acquisitions. For instance, in 2013, CHIESI Farmaceutici S.p.A acquired the Zymenex A/S and entered into the treatment of rare disease market.

The report on the global alpha mannosidosis market discussed individual strategies, followed by company profile of manufacturer of alpha mannosidosis. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global alpha mannosidosis market.

Alpha Mannosidosis Market: Snapshot

Alpha mannosidosis is a rare genetic disorder, categorized as a lysosomal storage disorder. It is characterized by hearing loss, skeletal abnormalities, intellectual disability, coarse facial features, and ataxia. Some of the most common symptoms may include loss of hearing, distinctive facial features, mild to moderate intellectual disability, cerebellar disorders, and weakened immune system. Treatment solutions in global alpha mannosidosis market include various vaccinations, hearing aids, orthopedic assistance devices and equipment, speech therapy, antibiotics, glasses, and educational interventions. These products and services in global alpha mannosidosis market are only used when deemed necessary and professionals invite regular follow-ups to monitor patients’ health. Treatment solutions in global alpha mannosidosis market are based on the type of the disorder, which is classified into three types based on the severity of the symptoms. Type 1 is relatively mild, recognizable after the age of ten years, and displays a slow rate of progression. Type 2 is considered to be a moderate form, can be recognized before the age of ten, and includes myopathy and skeletal abnormalities. This is considered to be the most common forms of the disorder for treatment in global alpha mannosidosis market. Type 3 is considered to be severe, can manifest as loss in pregnancy or result in early death due to progressive central nervous system involvement.

Some of the most effective treatment options in global alpha mannosidosis market include peripheral blood stem cell transplantation and bone marrow transplant. Bone marrow transplant (BMT) is traditionally preferred method of treatment in global alpha mannosidosis market. Methods such as these are considered expensive as they rely on super specialty biomaterials and equipment to effectively administer. One of the emerging therapy solutions in global alpha mannosidosis market is enzyme replacement therapy. Increasing investments in research and development activities to promote discovering treatments for rare diseases is anticipated to propel the growth of global alpha mannosidosis market in coming years. However, high cost of treatments and lack of awareness regarding the alpha mannosidosis disorder can restrict the growth of global alpha mannosidosis market in near future.

Global Alpha mannosidosis Market - Segmentation

Treatment Type

Bone Marrow Transplant

Enzyme Replacement Therapy

Indication

Type I

Type II

Type III

End-user

Hospitals

Specialty Clinics

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of alpha mannosidosis market?

Alpha mannosidosis market to reach US$ 18.7 Mn by 2027.

What would be the CAGR of the alpha mannosidosis market during the forecast period?

Alpha mannosidosis market is anticipated to expand at a CAGR of 9.9% from 2019 to 2027.

What are the key factors driving the alpha mannosidosis market?

Alpha mannosidosis market is driven by increasing investment in rare disease treatment and patent-cliff.

Which region is expected to project the highest market share in the global alpha mannosidosis market?

North America accounted for major share of the global alpha mannosidosis market in 2018, owing to high prevalence rates.

Which is the rising prominent segment in the alpha mannosidosis market?

The bone marrow transplant segment dominated the global alpha mannosidosis market in 2018 and the trend is projected to continue during the forecast period.

    1. Preface

    2. Executive Summary

    3. Research Methodology

    4. Market Overview

        4.1. Introduction

        4.2. Market Dynamics

            4.2.1. Drivers

            4.2.2. Restraints

            4.2.3. Opportunity

        4.3. Alpha Mannosidosis Market Analysis and Forecasts, 2019-2027

        4.4. Porter’s Five Force Analysis

        4.5. Alpha Mannosidosis Market: Value Chain Analysis

        4.6. Alpha Mannosidosis Market: Pricing Analysis

    5. Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

    6. Alpha Mannosidosis Market Revenue (US$ Mn), By Treatment, 2019-2027

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Alpha Mannosidosis Market Value Share Analysis, By Treatment, 2019 & 2027

        6.4. Alpha Mannosidosis Market By Treatment, 2019 & 2027

            6.4.1. Bone Marrow Transplant 

            6.4.2. Enzyme Replacement Therapy

        6.5. Alpha Mannosidosis Market Attractiveness By Treatment, 

        6.6. Key Trends

    7. Alpha Mannosidosis Market Revenue (US$ Mn), By Indication, 2019-2027

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Alpha Mannosidosis Market Value Share Analysis, By Indication, 2019 & 2027

        7.4. Alpha Mannosidosis Market By Indication, 2019 & 2027

            7.4.1. Type I

            7.4.2. Type II

            7.4.3. Type III

        7.5. Alpha Mannosidosis Market Attractiveness By Indication 

        7.6. Key Trends

    8. Alpha Mannosidosis Market Revenue (US$ Mn), By End-user 2019-2027

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Alpha Mannosidosis Market Value Share Analysis, By End-user, 2019 & 2027

        8.4. Alpha Mannosidosis Market By End-user, 2019 & 2027

            8.4.1. Hospitals

            8.4.2. Specialty Clinics

        8.5. Alpha Mannosidosis Market Attractiveness By End-user

        8.6. Key Trends

    9. Alpha Mannosidosis Market Revenue (US$ Mn), By Geography, 2019-2027

    10. North America Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

        10.1. Key Findings

        10.2. Key Market Insights

        10.3. North America Alpha Mannosidosis Market  Value Share Analysis, By Treatment, 2019 & 2027

        10.4. North America Alpha Mannosidosis Market Forecast By  Indication  2019 & 2027

        10.5. North America Alpha Mannosidosis Market Forecast By  End-user 2019 & 2027

    11. Europe Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

        11.1. Key Findings

        11.2. Key Market Insights

        11.3. Europe Alpha Mannosidosis Market  Value Share Analysis, By Treatment, 2019 & 2027

        11.4. Europe Alpha Mannosidosis Market Forecast By  Indication  2019 & 2027

        11.5. Europe Alpha Mannosidosis Market Forecast By  End-user 2019 & 2027

    12. Asia Pacific Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

        12.1. Key Findings

        12.2. Key Market Insights

        12.3. Asia Pacific Alpha Mannosidosis Market  Value Share Analysis, By Treatment, 2019 & 2027

        12.4. Asia Pacific Alpha Mannosidosis Market Forecast By  Indication  2019 & 2027

        12.5. Asia Pacific Alpha Mannosidosis Market Forecast By  End-user 2019 & 2027

    13. Latin America Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

        13.1. Key Findings

        13.2. Key Market Insights

        13.3. Latin America Alpha Mannosidosis Market  Value Share Analysis, By Treatment, 2019 & 2027

        13.4. Latin America Alpha Mannosidosis Market Forecast By  Indication  2019 & 2027

        13.5. Latin America Alpha Mannosidosis Market Forecast By  End-user 2019 & 2027

    14. Middle East and Africa Alpha Mannosidosis Market Revenue (US$ Mn), 2019-2027

        14.1. Key Findings

        14.2. Key Market Insights

        14.3. Middle East and Africa Alpha Mannosidosis Market  Value Share Analysis, By Treatment, 2019 & 2027

        14.4. Middle East and Africa Alpha Mannosidosis Market Forecast By  Indication  2019 & 2027

        14.5. Middle East and Africa Alpha Mannosidosis Market Forecast By  End-user 2019 & 2027

    15. Company Profiles

        15.1. Zymenex A/S (CHIESI Farmaceutici S.p.A.)

            15.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.1.2. Growth Strategies

            15.1.3. SWOT Analysis

    List of Table

    Table 01 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Treatment, 2019–2027

    Table 02 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Indication, 2019–2027

    Table 03 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By End-user, 2019–2027

    Table 04 Alpha Mannosidosis Market Size (US$ Mn) Forecast, By Geography, 2019–2027

    Table 05 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2019–2027

    Table 06 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2019–2027

    Table 07 North America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2019–2027

    Table 08 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2019–2027

    Table 09 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication, 2019–2027

    Table 10 Europe Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2019–2027

    Table 11 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2019–2027

    Table 12 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2019–2027

    Table 13 Asia Pacific Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2019–2027

    Table 14 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2019–2027

    Table 15 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2019–2027

    Table 16 Latin America Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2019–2027

    Table 17 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Treatment ,2019–2027

    Table 18 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By Indication ,2019–2027

    Table 19 Middle East & Africa Alpha Mannosidosis Market Size (US$ Mn) and Forecast, By End-user,2019–2027

    List of Figure

    Figure 01 Alpha Mannosidosis Market Snapshot

    Figure 02 Alpha Mannosidosis Market Size (US$ Mn) and Forecast, 2019–2027

    Figure 03 Alpha Mannosidosis Treatment Market Revenue (US$ Mn) and Y-o-Y growth (%), Bone Marrow Transplant (BMT) 2019–2027

    Figure 04 Alpha Mannosidosis Treatment Market Revenue (US$ Mn) and Y-o-Y growth (%),Enzyme Replacement Therapy (ERT) 2019–2027

    Figure 05 Alpha Mannosidosis Market Attractiveness Analysis By Treatment

    Figure 06 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%),Type I, 2019–2027

    Figure 07 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%),Type II, 2019–2027

    Figure 08 Alpha Mannosidosis Indication Market Revenue (US$ Mn) and Y-o-Y growth (%), Type III, 2019–2027

    Figure 09 Alpha Mannosidosis Market Attractiveness Analysis By Indication

    Figure 10 Alpha Mannosidosis End-user Market Revenue (US$ Mn) and Y-o-Y growth (%),Hospitals, 2019–2027

    Figure 11 Alpha Mannosidosis End-user Market Revenue (US$ Mn) and Y-o-Y growth (%),Specialty Clinics, 2019–2027

    Figure 12 Alpha Mannosidosis Market Attractiveness Analysis By End-user

    Figure 13 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%), North America, 2019–2027

    Figure 14 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Europe, 2019–2027

    Figure 15 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Asia Pacific, 2019–2027

    Figure 16 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Latin America, 2019–2027

    Figure 17 Alpha Mannosidosis Market Revenue (US$ Mn) and Y-o-Y growth (%),Middle East & Africa, 2019–2027

    Figure 18 North America Alpha Mannosidosis Value Share Analysis, By Treatment, 2019 and 2027

    Figure 19 North America Alpha Mannosidosis Value Share Analysis, By Indication, 2019 and 2027

    Figure 20 North America Alpha Mannosidosis Value Share Analysis, By End-user, 2019 and 2027

    Figure 21 Europe Alpha Mannosidosis Value Share Analysis, By Treatment, 2019 and 2027

    Figure 22 Europe Alpha Mannosidosis Value Share Analysis, By Indication, 2019 and 2027

    Figure 23 Europe Alpha Mannosidosis Value Share Analysis, By End-user, 2019 and 2027

    Figure 24 Asia Pacific Alpha Mannosidosis Value Share Analysis, By Treatment, 2019 and 2027

    Figure 25 Asia Pacific Alpha Mannosidosis Value Share Analysis, By Indication, 2019 and 2027

    Figure 26 Asia Pacific Alpha Mannosidosis Value Share Analysis, By End-user, 2019 and 2027

    Figure 27 Latin America Alpha Mannosidosis Value Share Analysis, By Treatment, 2019 and 2027

    Figure 28 Latin America Alpha Mannosidosis Value Share Analysis, By Indication, 2019 and 2027

    Figure 29 Latin America Alpha Mannosidosis Value Share Analysis, By End-user, 2019 and 2027

    Figure 30 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By Treatment, 2019 and 2027

    Figure 31 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By Indication, 2019 and 2027

    Figure 32 Middle East & Africa Alpha Mannosidosis Value Share Analysis, By End-user, 2019 and 2027

Copyright © Transparency Market Research, Inc. All Rights reserved

Alpha Mannosidosis Market

Schedule a Call